Amanote Research
Register
Sign In
Prm228 - Extrapolation of Survival Curves Using External Information: Implementation of Guyot’s Method in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2346
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
H Cawston
V Genestier
P Dale
J Doan
B Malcolm
Publisher
Elsevier BV
Related search
Puk9 - Network Meta-Analysis of Treatments in Previously Untreated Advanced or Metastatic Renal-Cell Carcinoma With Intermediate to Poor Prognosis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn6 - Systematic Literature Review of Efficacy & Safety Data for the Treatment of Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Spotlight on Cabozantinib for Previously Untreated Advanced Renal Cell Carcinoma: Evidence to Date
Cancer Management and Research
Oncology
Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Mo2 - Modelling Overall Survival in Immunotherapy Using Parametric Techniques: Avelumab in Previously Treated Metastatic Merkel Cell Carcinoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prm245 - Extrapolation of Survival in the Context of Economic Modelling Using Bayesian Model Averaging: An Application in Renal Cell Carcinoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Application of Dynamic Modeling for Survival Estimation in Advanced Renal Cell Carcinoma
PLoS ONE
Multidisciplinary
Survival of Patients Receiving Systematic Therapy for Metachronous or Synchronous Metastatic Renal Cell Carcinoma: A Retrospective Analysis
BMC Cancer
Cancer Research
Oncology
Genetics
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
